# Olinvacimab With Pembrolizumab in Patients With mTNBC

> **NCT04986852** · PHASE2 · TERMINATED · sponsor: **PharmAbcine** · enrollment: 19 (actual)

## Conditions studied

- Metastatic Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Olinvacimab

## Key facts

- **NCT ID:** NCT04986852
- **Lead sponsor:** PharmAbcine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-30
- **Primary completion:** 2024-12-03
- **Final completion:** 2024-12-03
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Subject recruitment issues and follow-up study plans
- **Last updated:** 2025-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04986852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04986852, "Olinvacimab With Pembrolizumab in Patients With mTNBC". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04986852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*